Oxford Biomedica Past Earnings Performance
Past criteria checks 0/6
Oxford Biomedica's earnings have been declining at an average annual rate of -61.5%, while the Biotechs industry saw earnings growing at 15.3% annually. Revenues have been growing at an average rate of 14.5% per year.
Key information
-61.5%
Earnings growth rate
-56.2%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | 14.5% |
| Return on equity | -236.6% |
| Net Margin | -175.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Is Oxford Biomedica (LON:OXB) Using Debt Sensibly?
Oct 19
Oxford Biomedica plc (LON:OXB) Not Doing Enough For Some Investors As Its Shares Slump 28%
Aug 23Is Oxford Biomedica plc (LON:OXB) Expensive For A Reason? A Look At Its Intrinsic Value
Feb 15Is Oxford Biomedica (LON:OXB) Using Too Much Debt?
Oct 06Investors Shouldn't Be Too Comfortable With Oxford Biomedica's (LON:OXB) Robust Earnings
May 02We're Not Worried About Oxford Biomedica's (LON:OXB) Cash Burn
Jun 29We Think Oxford Biomedica (LON:OXB) Can Easily Afford To Drive Business Growth
Mar 09What Kind Of Shareholders Own Oxford Biomedica plc (LON:OXB)?
Feb 08Investors Who Bought Oxford Biomedica (LON:OXB) Shares Five Years Ago Are Now Up 202%
Dec 24
The Independent Non-Executive Director of Oxford Biomedica plc (LON:OXB), Andrew John Heath, Just Sold 79% Of Their Holding
Dec 02Oxford Biomedica (LON:OXB) Is In A Good Position To Deliver On Growth Plans
Dec 01Revenue & Expenses BreakdownBeta
How Oxford Biomedica makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 90 | -157 | 25 | 103 |
| 30 Sep 23 | 104 | -110 | 25 | 110 |
| 30 Jun 23 | 119 | -62 | 25 | 117 |
| 31 Mar 23 | 130 | -50 | 24 | 106 |
| 31 Dec 22 | 140 | -39 | 23 | 95 |
| 30 Sep 22 | 133 | -32 | 21 | 82 |
| 30 Jun 22 | 126 | -25 | 19 | 69 |
| 31 Mar 22 | 134 | -3 | 17 | 58 |
| 31 Dec 21 | 143 | 19 | 14 | 47 |
| 30 Sep 21 | 139 | 19 | 13 | 41 |
| 30 Jun 21 | 135 | 19 | 13 | 34 |
| 31 Mar 21 | 111 | 6 | 12 | 37 |
| 31 Dec 20 | 88 | -6 | 11 | 40 |
| 30 Sep 20 | 77 | -9 | 12 | 39 |
| 30 Jun 20 | 66 | -13 | 13 | 38 |
| 31 Mar 20 | 65 | -14 | 12 | 34 |
| 31 Dec 19 | 64 | -16 | 12 | 30 |
| 30 Sep 19 | 64 | -12 | 10 | 26 |
| 30 Jun 19 | 64 | -8 | 9 | 22 |
| 31 Mar 19 | 65 | 0 | 8 | 20 |
| 31 Dec 18 | 67 | 8 | 7 | 19 |
| 30 Sep 18 | 62 | 4 | 7 | 22 |
| 30 Jun 18 | 57 | 0 | 7 | 25 |
| 31 Mar 18 | 47 | -5 | 7 | 23 |
| 31 Dec 17 | 38 | -9 | 7 | 22 |
| 30 Sep 17 | 34 | -10 | 6 | 22 |
| 30 Jun 17 | 31 | -11 | 5 | 22 |
| 31 Mar 17 | 29 | -14 | 6 | 23 |
| 31 Dec 16 | 28 | -17 | 6 | 24 |
| 30 Sep 16 | 26 | -16 | 7 | 24 |
| 30 Jun 16 | 24 | -16 | 8 | 24 |
| 31 Mar 16 | 20 | -15 | 7 | 22 |
| 31 Dec 15 | 16 | -13 | 7 | 20 |
| 30 Sep 15 | 15 | -12 | 6 | 20 |
| 30 Jun 15 | 13 | -10 | 5 | 19 |
| 31 Mar 15 | 13 | -9 | 4 | 18 |
| 31 Dec 14 | 14 | -9 | 4 | 17 |
| 30 Sep 14 | 11 | -9 | 4 | 15 |
| 30 Jun 14 | 8 | -10 | 3 | 14 |
| 31 Mar 14 | 7 | -11 | 3 | 14 |
| 31 Dec 13 | 5 | -11 | 3 | 14 |
| 30 Sep 13 | 5 | -10 | 3 | 14 |
| 30 Jun 13 | 5 | -10 | 3 | 14 |
Quality Earnings: OXB is currently unprofitable.
Growing Profit Margin: OXB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OXB is unprofitable, and losses have increased over the past 5 years at a rate of 61.5% per year.
Accelerating Growth: Unable to compare OXB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OXB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: OXB has a negative Return on Equity (-236.61%), as it is currently unprofitable.